Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27655236 | 0.88 | PDE4B (0.42) | PDE4APDE4BPDE4DPDE4CKMT2A | |
| SCHEMBL4366101 | 0.78 | ALDH1A1 (0.46) | PDE4APDE4BPDE4DPDE4CKMT2A | |
| SCHEMBL1766161 | 0.77 | IDO1 (0.45) | KMT2A | |
| SCHEMBL2902645 | 0.76 | PDE5A (0.46) | PDE4APDE4BPDE4DPDE4CKMT2A | |
| SCHEMBL2908581 | 0.74 | SLC6A2 (0.52) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL28839771 | 0.73 | ABCB1 (0.42) | KMT2A | |
| SCHEMBL3679926 | 0.73 | PDE4B (0.48) | PDE4APDE4BPDE4DPDE4CKMT2A | |
| SCHEMBL6876868 | 0.72 | PDE4A (0.44) | PDE4APDE4BPDE4DPDE4CKMT2A | |
| SCHEMBL30127258 | 0.72 | SLC6A2 (0.38) | — | |
| SCHEMBL8480514 | 0.72 | ALDH1A1 (0.43) | PDE4APDE4BPDE4DPDE4CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| CN-1922144-A | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | MEMORY PHARM CORP (US) | 2007-02-28 | — | — | CN | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4D 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.